Oxular Completes Financing Round Worth $37 million
Oxular has raised US $37 million in a financing round led by specialist life sciences investor, Forbion.
Retinal therapeutics development company, Oxular, has announced in a March 1, 2021 press release that it has raised US $37 million in a financing round led by specialist life sciences investor, Forbion.
The monies raised will be used to fund Phase II clinical studies evaluating the company’s 12-month treatment for diabetic macular edema (DME), OXU-001. The studies are expected to start later in 2021. Additionally, funds will be allocated to progressing the company’s early-product pipeline.
“We are pleased to add such a renowned investor as Forbion to our already supportive investor base, including IP Group, NeoMed, and V-Bio Ventures,” said Thomas Cavanagh, CEO of Oxular, in the press release. “These are experienced healthcare investors who see the potential of Oxular’s disruptive technology and innovative treatment approach—which is tissue-specific delivery of potent drug products that safely provide up to 12-months’ treatment durability for retinal disease.”
“Oxular has built an exceptional platform that has the potential to unlock the full therapeutic potential of potent molecules and significantly improve patients’ lives by providing safe, efficacious and convenient treatment options,” added Dr. Dmitrij Hristodorov, principal at Forbion and non-executive director at Oxular, in the press release. “We are pleased to lead this financing round and look forward to seeing the progress that the team at Oxular makes over the coming years, in both its clinical and preclinical programs.”
Source: Oxular
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
